Literature DB >> 22399793

Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion.

Baber K Khan1, Jennifer S Yokoyama, Leonel T Takada, Sharon J Sha, Nicola J Rutherford, Jamie C Fong, Anna M Karydas, Teresa Wu, Robin S Ketelle, Matthew C Baker, Mariely-Dejesus Hernandez, Giovanni Coppola, Daniel H Geschwind, Rosa Rademakers, Suzee E Lee, Howard J Rosen, Gil D Rabinovici, William W Seeley, Katherine P Rankin, Adam L Boxer, Bruce L Miller.   

Abstract

BACKGROUND: Some patients meeting behavioural variant frontotemporal dementia (bvFTD) diagnostic criteria progress slowly and plateau at mild symptom severity. Such patients have mild neuropsychological and functional impairments, lack characteristic bvFTD brain atrophy and have thus been referred to as bvFTD 'phenocopies' or slowly progressive (bvFTD-SP). The few patients with bvFTD-SP that have been studied at autopsy have demonstrated no evidence of FTD pathology, suggesting that bvFTD-SP is neuropathologically distinct from other forms of FTD. Here, two patients with bvFTD-SP with chromosome 9 open reading frame 72 (C9ORF72) hexanucleotide expansions are described.
METHODS: 384 patients with an FTD clinical spectrum and Alzheimer's disease diagnoses were screened for C9ORF72 expansion. Two bvFTD-SP mutation carriers were identified. Neuropsychological and functional data, as well as brain atrophy patterns, assessed using voxel based morphometry (VBM), were compared with 44 patients with sporadic bvFTD and 85 healthy controls.
RESULTS: Both patients were aged 48 years at baseline and met possible bvFTD criteria. In the first patient, VBM revealed thalamic and posterior insula atrophy. Over 7 years, his neuropsychological performance and brain atrophy remained stable. In the second patient, VBM revealed cortical atrophy with subtle frontal and insular volume loss. Over 2 years, her neuropsychological and functional scores as well as brain atrophy remained stable.
CONCLUSIONS: C9ORF72 mutations can present with a bvFTD-SP phenotype. Some bvFTD-SP patients may have neurodegenerative pathology, and C9ORF72 mutations should be considered in patients with bvFTD-SP and a family history of dementia or motor neuron disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22399793      PMCID: PMC3388906          DOI: 10.1136/jnnp-2011-301883

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  30 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Reliability and validity of The Awareness of Social Inference Test (TASIT): a clinical test of social perception.

Authors:  Skye McDonald; Cristina Bornhofen; David Shum; Esther Long; Clare Saunders; Kerryn Neulinger
Journal:  Disabil Rehabil       Date:  2006-12-30       Impact factor: 3.033

3.  Measurement of functional activities in older adults in the community.

Authors:  R I Pfeffer; T T Kurosaki; C H Harrah; J M Chance; S Filos
Journal:  J Gerontol       Date:  1982-05

Review 4.  The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Authors:  J L Cummings
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

5.  Movement and mind: a functional imaging study of perception and interpretation of complex intentional movement patterns.

Authors:  F Castelli; F Happé; U Frith; C Frith
Journal:  Neuroimage       Date:  2000-09       Impact factor: 6.556

6.  Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease.

Authors:  Joel H Kramer; Jennifer Jurik; Sharon J Sha; Kate P Rankin; Howard J Rosen; Julene K Johnson; Bruce L Miller
Journal:  Cogn Behav Neurol       Date:  2003-12       Impact factor: 1.600

7.  Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging.

Authors:  Rhys R Davies; Christopher M Kipps; Joanna Mitchell; Jillian J Kril; Glenda M Halliday; John R Hodges
Journal:  Arch Neurol       Date:  2006-11

8.  Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale.

Authors:  Christopher M Kipps; R Rhys Davies; Joanna Mitchell; Jillian J Kril; Glenda M Halliday; John R Hodges
Journal:  Dement Geriatr Cogn Disord       Date:  2007-03-19       Impact factor: 2.959

9.  Behavioural variant frontotemporal dementia: not all it seems?

Authors:  C M Kipps; P J Nestor; T D Fryer; J R Hodges
Journal:  Neurocase       Date:  2007-08       Impact factor: 0.881

View more
  81 in total

Review 1.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 2.  C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity.

Authors:  Jennifer S Yokoyama; Daniel W Sirkis; Bruce L Miller
Journal:  Am J Neurodegener Dis       Date:  2014-03-28

Review 3.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

Review 4.  How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?

Authors:  Marka van Blitterswijk; Mariely DeJesus-Hernandez; Rosa Rademakers
Journal:  Curr Opin Neurol       Date:  2012-12       Impact factor: 5.710

5.  C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.

Authors:  Elaine Y Liu; Jenny Russ; Kathryn Wu; Donald Neal; Eunran Suh; Anna G McNally; David J Irwin; Vivianna M Van Deerlin; Edward B Lee
Journal:  Acta Neuropathol       Date:  2014-05-08       Impact factor: 17.088

6.  Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype.

Authors:  Nicola J Rutherford; Michael G Heckman; Mariely Dejesus-Hernandez; Matt C Baker; Alexandra I Soto-Ortolaza; Sruti Rayaprolu; Heather Stewart; Elizabeth Finger; Kathryn Volkening; William W Seeley; Kimmo J Hatanpaa; Catherine Lomen-Hoerth; Andrew Kertesz; Eileen H Bigio; Carol Lippa; David S Knopman; Hans A Kretzschmar; Manuela Neumann; Richard J Caselli; Charles L White; Ian R Mackenzie; Ronald C Petersen; Michael J Strong; Bruce L Miller; Bradley F Boeve; Ryan J Uitti; Kevin B Boylan; Zbigniew K Wszolek; Neill R Graff-Radford; Dennis W Dickson; Owen A Ross; Rosa Rademakers
Journal:  Neurobiol Aging       Date:  2012-07-26       Impact factor: 4.673

Review 7.  Dementia and neuroimaging.

Authors:  Federica Agosta; Francesca Caso; Massimo Filippi
Journal:  J Neurol       Date:  2012-12-15       Impact factor: 4.849

Review 8.  Clinical diagnostic criteria and classification controversies in frontotemporal lobar degeneration.

Authors:  Katya Rascovsky; Murray Grossman
Journal:  Int Rev Psychiatry       Date:  2013-04

Review 9.  Neuroimaging features of C9ORF72 expansion.

Authors:  Jennifer S Yokoyama; Howard J Rosen
Journal:  Alzheimers Res Ther       Date:  2012-11-16       Impact factor: 6.982

Review 10.  The neurogenetics of atypical parkinsonian disorders.

Authors:  Brent L Fogel; Mary C Clark; Daniel H Geschwind
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.